The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Intravenous Immunoglobulin Market Increase Between 2026 And 2030?
The intravenous immunoglobulin market has experienced significant expansion in recent years. It is projected to expand from $15.57 billion in 2025 to $16.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.3%. Historically, this growth has been driven by factors such as the increasing occurrence of primary immunodeficiency diseases, improvements in immunoglobulin purification methods, a rise in hospital-based IVIG administrations, greater understanding of autoimmune disorders, and the enlargement of IVIG manufacturing facilities.
The intravenous immunoglobulin market size is anticipated to undergo significant expansion in the coming years, with projections indicating it will reach **$23.44 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%**. This projected growth throughout the forecast period stems from factors such as increasing demand for home-based IVIG therapy, the development of biosimilar IVIG products, the integration of automated infusion technologies, an expansion of applications in neurological disorders, and the growth of immunoglobulin therapies in emerging markets. Noteworthy trends for this period include personalized immunoglobulin therapy, IVIG administration in home settings, the development and adoption of biosimilars, enhanced purification and safety protocols, and automated infusion systems.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp
Which Strategic Drivers Are Supporting The Intravenous Immunoglobulin Market Development?
The escalating demographic of older individuals is projected to propel the intravenous immunoglobulin market. The geriatric population specifically encompasses those aged over 65 years. As individuals advance in age, their immune systems often become compromised, leading to a shortage of antibodies. Consequently, immunoglobulins are required to supplement these essential antibodies, thereby elevating the demand for intravenous immunoglobulins and fostering growth in the intravenous immunoglobulin market. For instance, data from January 2024, provided by the Population Reference Bureau, a Kenya-based Nonprofit organization, indicates that the number of Americans aged 65 and older is anticipated to climb from 58 million in 2022 to 82 million by 2050, representing a 47% expansion. Concurrently, this age group’s proportion of the total population is also expected to increase from 17% to 23% within the identical timeframe. Therefore, the expanding geriatric population will undoubtedly stimulate the advancement of the intravenous immunoglobulin market.
Which Segment Divisions Form The Structure Of The Intravenous Immunoglobulin Market?
The intravenous immunoglobulin market covered in this report is segmented –
1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications
4) By End-User: Hospitals, Clinics, Home Care
What Trends Are Affecting The Intravenous Immunoglobulin Market Dynamics?
Major companies operating in the intravenous immunoglobin market are focused on introducing innovative products, such as plasma-derived medicines, and getting them approved by federal agencies, including the US FDA, to gain a competitive edge in the market. The introduction of an FDA-approved innovative IVIG solution represents the approval of a novel intravenous immunoglobulin (IVIG) therapy by the U.S. Food and Drug Administration for the treatment of specific medical conditions. For instance, in June 2024, Biotest AG, a Germany-based supplier of plasma proteins and products company, announced its first U.S. Food and Drug Administration (FDA) approval for Yimmugo, intended for the treatment of primary immunodeficiencies. As an intravenous immunoglobulin, Yimmugo contains pooled human plasma-derived immunoglobulin G (IgG), which plays a crucial role in immune support for patients with PIDs. This approval occurs amid increasing demand for plasma-derived therapies, highlighting the need for effective treatments for patients with compromised immune systems. Yimmugo adds to Grifols’ existing range of intravenous and subcutaneous immunoglobulins, providing more options for patients reliant on these essential medicines.
Which Companies Are Engaged In The Intravenous Immunoglobulin Market Environment?
Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.
Access The Complete Intravenous Immunoglobulin Market Report:
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Which Area Represents The Largest Portion Of The Intravenous Immunoglobulin Market?
North America was the largest region in the intravenous immunoglobulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Intravenous Immunoglobulin Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp
Browse Through More Reports Similar to the Global Intravenous Immunoglobulin Market 2026, By The Business Research Company
Intravenous Immunoglobulin Market Report 2026
https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report
Immunoglobulins Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoglobulins-global-market-report
Subcutaneous Immunoglobulin Scig Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model